Simply Wall St.
What Catalysts Are Changing the Story for Sight Sciences Investors?
📈
AI Sentiment
Highly Positive
8/10
- Home
- SGHT
SGHT
Sight Sciences Inc.
as of 11-28-2025 12:12pm EST
$8.30
$0.09
-1.07%
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.
Chart Type:
Time Range:
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | MENLO PARK |
| Market Cap: | 193.2M | IPO Year: | 2021 |
| Target Price: | $4.93 | AVG Volume (30 days): | 251.7K |
| Analyst Decision: | Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.89 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.03 - $8.80 | Next Earning Date: | 11-06-2025 |
| Revenue: | $76,052,000 | Revenue Growth: | -4.39% |
| Revenue Growth (this year): | -5.47% | Revenue Growth (next year): | 12.04% |
AI-Powered SGHT Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 3 days ago
AI Recommendation
hold
Model Accuracy: 71.72%
71.72%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Sight Sciences Inc. (SGHT)
Taylor Brenton
Sell
EVP, Operations & R&D
SGHT Nov 17, 2025
Avg Cost/Share
$7.06
Shares
14,418
Total Value
$101,791.08
Owned After
170,831
SEC Form 4
Taylor Brenton
Sell
EVP, Operations & R&D
SGHT Oct 6, 2025
Avg Cost/Share
$3.37
Shares
591
Total Value
$1,991.67
Owned After
170,831
SEC Form 4
HAYDEN JEREMY B.
Sell
Chief Legal Officer
SGHT Oct 3, 2025
Avg Cost/Share
$3.27
Shares
9,731
Total Value
$31,820.37
Owned After
256,590
SEC Form 4
Badawi David
Sell
Chief Technology Officer
SGHT Oct 3, 2025
Avg Cost/Share
$3.27
Shares
6,033
Total Value
$19,727.91
Owned After
1,864,992
SEC Form 4
Bauerlein Alison
Sell
Chief Financial Officer
SGHT Oct 2, 2025
Avg Cost/Share
$3.30
Shares
19,948
Total Value
$65,828.40
Owned After
597,520
SEC Form 4
Badawi Paul
Sell
President and CEO
SGHT Oct 1, 2025
Avg Cost/Share
$3.34
Shares
24,441
Total Value
$81,632.94
Owned After
5,962,502
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Taylor Brenton | SGHT | EVP, Operations & R&D | Nov 17, 2025 | Sell | $7.06 | 14,418 | $101,791.08 | 170,831 | |
| Taylor Brenton | SGHT | EVP, Operations & R&D | Oct 6, 2025 | Sell | $3.37 | 591 | $1,991.67 | 170,831 | |
| HAYDEN JEREMY B. | SGHT | Chief Legal Officer | Oct 3, 2025 | Sell | $3.27 | 9,731 | $31,820.37 | 256,590 | |
| Badawi David | SGHT | Chief Technology Officer | Oct 3, 2025 | Sell | $3.27 | 6,033 | $19,727.91 | 1,864,992 | |
| Bauerlein Alison | SGHT | Chief Financial Officer | Oct 2, 2025 | Sell | $3.30 | 19,948 | $65,828.40 | 597,520 | |
| Badawi Paul | SGHT | President and CEO | Oct 1, 2025 | Sell | $3.34 | 24,441 | $81,632.94 | 5,962,502 |
Latest Sight Sciences Inc. News
SGHT Breaking Stock News: Dive into SGHT Ticker-Specific Updates for Smart Investing
Compare SGHT vs Leading Stocks
See how SGHT stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "SGHT Sight Sciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.